<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533633</url>
  </required_header>
  <id_info>
    <org_study_id>2017-838R-MA</org_study_id>
    <nct_id>NCT04533633</nct_id>
  </id_info>
  <brief_title>German Epicardial Collateral CTO Registry</brief_title>
  <acronym>EPIC</acronym>
  <official_title>German Multicentre Registry to Evaluate the Technical Feasibilty of Epicardial Collateral Connections in CTO PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universit채tsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Heart Center Freiburg - Bad Krozingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universit채tsmedizin Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EPIC registry is an observational multicentre registry evaluating the technical&#xD;
      feasibility of retrograde CTO-PCI using epicardial collateral connections. It will evaluate&#xD;
      the frequency, effectiveness, safety and outcomes of patients who underwent CTO-PCI using&#xD;
      this approach. The EPIC registry retrieves data from CTO centres across Germany.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EPIC registry is the first German-wide observational multicentre registry evaluating the&#xD;
      technical feasibility, clinical success and safety of retrograde CTO-PCI using epicardial&#xD;
      collateral connections. The EPIC registry retrieves data from CTO centres across Germany. All&#xD;
      patients will be followed-up to 30 days after inclusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of technically successful retrograde CTO-PCI using epicaridal collaterals</measure>
    <time_frame>30 days</time_frame>
    <description>defined as the rate of successful CTO-PCI with reestablished antegrade coronary flow (thrombolysis in myocardial infarction (TIMI) flow III) with less than residual stenosis of 50%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of clinically successful retrograde CTO-PCI using epicaridal collaterals</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical success is defined as the rate of successful CTO-PCI by technical success without MACCE and without major periprocedural complications, including pericardial tamponade and contrast induced dialysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of failed retrograde CTO-PCI using epicaridal collaterals</measure>
    <time_frame>30 days</time_frame>
    <description>is defined as the rate of CTO-PCI without technical success defined as residual stenosis &gt;50% (by visual estimation) and TIMI flow grade &lt;3 after CTO-PCI.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Chronic Total Occlusion</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Retrograde Percutaneous Coronary Intervention of Chronic Total Occlusion</intervention_name>
    <description>Retrograde CTO-PCI using epicardial collateral connections</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        EPIC will observationally evaluate all patients undergoing retrograde CTO-PCI using&#xD;
        epicardial collateral connections during daily clinical practice from German CTO centres.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients undergoing retrograde CTO-PCI using epicardial collateral connections&#xD;
             during daily clinical practice.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Michael Behnes, Prof. Dr.</last_name>
    <phone>+49 621 383 6239</phone>
    <email>michael.behnes@umm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kambis Mashayekhi, Dr.</last_name>
    <phone>+49 7633 402 2100</phone>
    <email>Kambis.Mashayekhi@universitaets-herzzentrum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Centre Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden W체rttemberg</state>
        <zip>76149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Behnes</last_name>
      <phone>+496213836239</phone>
      <email>michael.behnes@umm.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 23, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>August 29, 2020</last_update_submitted>
  <last_update_submitted_qc>August 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universit채tsmedizin Mannheim</investigator_affiliation>
    <investigator_full_name>Michael Behnes</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

